MY008211A not checked

Wuhan Createrna Science and Technology Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
5 active
11 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“MY008211A tablets Participants will receive MY008211A at a dose of 400 mg orally b.i.d”In the company’s words, NCT06932471 on ClinicalTrials.gov
Tested for
Paroxysmal Nocturnal Hemoglobinuria (PNH) (2 trials), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH), IgA Nephropathy (IgAN)
Main trialPhase 3
“The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.”In the company’s words, NCT06932471 on ClinicalTrials.gov
Other names
no other name · no name

Other drugs for Paroxysmal Nocturnal Hemoglobinuria (PNH)

All 23 drugs for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Dec 2025 Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Phase 3Recruiting 30 Dec 2025 Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
Phase 2/3Recruiting 30 Dec 2026 Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 2Not yet recruiting 15 Jun 2026 Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Phase 2Not yet recruiting Jul 2027 Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2Completed 30 Apr 2024 A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1Completed 23 Oct 2022 Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects
Phase 1Completed 4 Jun 2023 A Study of Single-dose MY008211A in Healthy Adults
Phase 1Completed 30 Jun 2023 A Study of Multiple Ascending Doses MY008211A in Healthy Adults
Phase 1Unknown 27 Sep 2024 To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects
Phase 1Completed 28 Dec 2024 A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MY008211A

Following is part of Solo: you see every change to MY008211A the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in